Experiment Analysis & Result Interpretation Questions

Approach: For each user, compute total revenue in the 14 days after their user.created_at (post-exposure) and join to variant to get per-user RPU. Then aggregate mean RPU by variant. For significance, run a two-sample test (preferably non-parametric or bootstrap) on user-level RPU, and report effect size and CI.

SQL (BigQuery/Postgres style):

WITH user_revenue AS (
  SELECT
    u.user_id,
    u.variant,
    SUM(o.amount) AS rpu
  FROM users u
  LEFT JOIN orders o
    ON o.user_id = u.user_id
   AND o.placed_at >= u.created_at
   AND o.placed_at < u.created_at + INTERVAL '14' DAY
  GROUP BY u.user_id, u.variant
)
SELECT
  variant,
  COUNT(*) AS users,
  SUM(rpu) AS total_revenue,
  AVG(rpu) AS mean_rpu,
  PERCENTILE_CONT(0.5) WITHIN GROUP (ORDER BY rpu) AS median_rpu,
  STDDEV_POP(rpu) AS sd_rpu
FROM user_revenue
GROUP BY variant;

Statistical testing:

• Use user-level RPU as independent observations.
• If distribution is skewed or many zeros, prefer bootstrapped difference in means or a Mann–Whitney U test. Example: bootstrap the mean difference (treatment - control) with 10k resamples to get 95% CI and p-value.
• Adjust for multiple comparisons and consider covariate adjustment (age, signup cohort) via regression (e.g., OLS on log(1+RPU) or a two-part model: probability of purchase (logistic) and conditional spend (Gamma/OLS)).

Recommended next steps if treatment RPU decreased significantly:

• Quantify business impact (absolute revenue loss, per-week/month extrapolation).
• Investigate drivers: conversion rate, average order value, order frequency, user segments (cohort, device, geography).
• Roll back or pause treatment if risk is high while debugging.
• Run exploratory analyses (funnel, product mix, retention) and run targeted follow-ups (A/B test variants, smaller rollback experiments).
• Communicate findings with stakeholders including confidence intervals, power, and suggested corrective actions.

Situation: We ran an A/B test of a new treatment. The uplift in the primary metric was positive but non-significant (p = 0.12) and post-hoc power is low — so the data are inconclusive rather than evidence of no effect.

Recommendation to executives (clear, non-technical):

• The point estimate suggests potential upside, but statistical evidence is weak due to insufficient sample size/noise. I do not recommend a full rollout yet; instead, pursue targeted follow-ups to reduce uncertainty while minimizing business risk.

What I'll present (visual + verbal):

• Point estimate with 95% confidence interval and a simple interpretation: “Estimated uplift = +X% (95% CI: -Y% to +Z%).”
• Power/MDE summary: show achieved power and the minimum detectable effect (MDE) at our sample size.
• Expected Value analysis: combine the point estimate with business impact (revenue per user, cost of rollout) to show expected gain/loss under uncertainty.

Proposed next analyses and experiments:

1. Variance reduction: re-examine metric definition, filter noisy segments, use covariate adjustment (ANCOVA) or CUPED to improve sensitivity.
2. Pre-specified subgroup analysis: test high-value cohorts where treatment could be stronger (but pre-register to avoid p-hacking).
3. Extend the experiment or run an additional A/B test sized to detect a realistic MDE (power calc: choose MDE based on business thresholds, e.g., 80% power at α=0.05).
4. Sequential or Bayesian approach: consider a Bayesian analysis to report a credible interval and probability uplift > business threshold (e.g., P(uplift > 1%) = 72%).
5. Funnel / leading indicators: examine upstream metrics (engagement, add-to-cart) for earlier signal and consistency.

Quantifying uncertainty in recommendation:

• Report confidence intervals and probability of beating the business-significant threshold (via Bayesian posterior or bootstrap).
• Provide expected value of two actions (rollout vs. more testing): EV = P(success)*benefit - P(failure)*cost, showing break-even probabilities.
• Recommend decision rule tied to business tolerance (e.g., only roll out if P(uplift > MDE) > 90% or EV positive).

Next steps I’d take this week:

• Deliver a one-page executive slide with CI, MDE/power, EV table, and 2 recommended options (extend & optimize test vs. targeted pilot).
• If they prefer quicker learning, run a scaled pilot in top 10% of users with improved metric and covariate adjustment; otherwise, scope a full-powered follow-up test.

This balances honest communication of uncertainty, practical next steps to reduce noise, and a business-driven decision framework.

Situation: I was supporting a pricing experiment dashboard for a retail product that showed a strong uplift in conversion and revenue. Stakeholders wanted to expand the experiment to more markets immediately, but I found patterns that suggested the uplift might be driven by disproportionate impact on specific demographic groups — potentially discriminatory pricing — which posed legal, ethical, and reputational risk.

Task: My responsibility was to assess whether the experiment signals were valid and safe to scale, and to recommend whether we should stop the experiment.

Action:

• Evaluated the evidence: I ran cohort breakdowns (age, ZIP, device, returning vs new customers), checked randomization balance, re-ran statistical tests with multiple-hypothesis correction, and reviewed data lineage to rule out instrumentation errors. The uplift persisted but was concentrated in a few protected-region ZIPs and new-customer cohorts; randomization was skewed due to a rollout script bug.
• Assessed risk: I consulted compliance/legal with initial findings and produced a concise risk matrix quantifying legal, customer trust, and revenue impacts if continued.
• Communicated the decision: I prepared a one-page executive summary and a short deck with clear visuals: the cohort charts, imbalance evidence, and p-values. In a stakeholder meeting I explained why the skew invalidated causal claims and the potential harms of scaling. I recommended pausing the rollout, rolling back the pricing change for affected cohorts, and running a controlled re-randomized test after fixes.
• Implemented documentation: logged the decision and evidence in our experiment tracking system (with links to raw datasets, SQL queries, dashboard versions), filed a ticket for engineering to fix the randomization bug, and wrote a postmortem capturing timeline, root cause, decisions, and learnings.

Result: Stakeholders accepted the pause once the risk and data issues were clear. Engineering fixed the rollout logic, we re-randomized and re-ran the experiment with pre-registered analysis, and subsequent results showed a smaller, non-discriminatory uplift. The audit trail and postmortem were used in quarterly compliance review and informed a new checklist for experiment rollout.

What I learned: Present clear, quantified evidence, map risks to business outcomes, involve compliance early, and document everything so decisions are auditable and future experiments are safer.

Situation: You run an A/B test where Variant increases engagement (stat. sig.) but lowers conversion (stat. sig.). Below is a structured BI-oriented approach to diagnose and recommend action.

1. Quick sanity diagnostics

• Confirm metrics definitions and windows (DAU, sessions, conversion window).
• Recompute significance with original data (bootstrap, Bayesian check) and check p-hacking or multiple-testing correction.
• Verify randomization balance on key covariates (country, device, traffic source).

2. Segmentation analysis

• Break down by cohort: new vs returning users, device, OS, country, acquisition channel, browser.
• Time-based segments: early vs late traffic, hourly/daily effects.
• Funnel-stage engagement: which engagement actions rose (time on site, clicks, scroll depth)?

3. Funnel checks

• Map user journeys: engagement events → micro-conversions → final conversion.
• Inspect drop-off points and conversion latency distributions.
• Cohort retention: did engagement lift cause more exploration but longer path to convert?

4. Instrumentation & data quality audit

• Confirm event deduplication, sampling, attribution windows.
• Check for missing events, event schema changes, or tag manager deployments coincident with test.
• Validate experiment assignment persistence (cookie/device id) and cross-device mapping.

5. Qualitative research

• Session replays, heatmaps for Variant to see confusing UI.
• User interviews or surveys on intent and friction.
• Support/ticket logs spikes correlated with Variant.

6. Hypotheses & further tests

• Hypothesize mechanisms (e.g., Variant increases browsing but introduces friction at checkout).
• Run targeted follow-ups: fix suspected friction, A/A test instrumentation fixes, or micro-experiments isolating features.

7. Decision criteria (rollout / rollback / iterate)

• Rollout if: conversion drop is not robust across key revenue segments, lift in engagement predicts long-term LTV increase (projected net revenue positive), instrumentation validated, no major UX issues.
• Rollback if: conversion drop persists across core revenue cohorts, negative impact on high-LTV segments, or uncovered instrumentation/bug causing loss.
• Further testing if: mixed signals (lift in some segments, drop in others), suspected instrumentation problems, or need to isolate causal element — prioritize quick follow-ups and guardrail metrics (revenue per user).

Deliverables: dashboard showing segmented KPI delta, funnel visualization with confidence intervals, instrumentation checklist, and prioritized test plan with expected impact and timeline.

1. Clarify scope & sanity checks

• Confirm the A/B test metric definitions, experiment period, sample sizes, randomization, and whether revenue is measured at same granularity (session vs. user vs. order).
• Recompute primary and secondary metrics to rule out instrumentation or attribution bugs.

2. Metrics to check (top-down)

• Conversion rate (CR) by cohort (user, session, visitor).
• Total revenue, revenue per user (RPU), revenue per converted user (AOV = revenue / orders), number of orders.
• Retention/return rate, churn, refund/return rates, and margin if available.
• Funnel step metrics (add-to-cart, checkout start, payment success).
• Traffic sources and campaign tags.

3. Segmentations to run

• New vs. returning users
• Device / platform (mobile, web, app)
• Geography, channel (organic, paid), and time-of-day
• Customer value segments (LTV quartiles), promo vs. non-promo orders
• Experiment exposure frequency and overlap with other experiments

4. Detect cannibalization vs. AOV decline

• Cannibalization: Look for shifts in where conversions occur—if treatment increases conversions for low-margin or discounted SKUs or shifts buying from high-LTV channels to low-LTV channels. Compare incremental conversions by segment vs. incremental revenue. If CR↑ but RPU↓ and orders shifted to cheaper SKUs or promo buckets, suspect cannibalization.
• AOV decline: Check average order value per converted user and item-level revenue. If order count stable or up but AOV per order drops significantly (e.g., more single-item, lower-priced purchases), AOV decline is likely.
• Use decomposition: ΔTotalRevenue = ΔConversions * baseline AOV + baseline Conversions * ΔAOV + interaction term. Quantify which term dominates.

5. Deeper analysis

• Item/sku-level lift analysis to see which products drove conversion and revenue delta.
• Time series by day to rule out short-term promotional confounds.
• Cohort post-conversion revenue (refunds, returns) and lifetime revenue if test window allows.

6. Decision criteria

• Rollout: treatment shows statistically significant positive lift in revenue (RPU/AOV) or at minimum no statistically significant negative impact on revenue/margin in main business segments; no harmful cannibalization; business stakeholders accept trade-offs.
• Further testing: conversion lift but revenue impact ambiguous or concentrated in specific segments; run follow-up experiments restricting to high-value segments or A/B/n to separate UI from pricing effects; extend duration to capture LTV.
• Rollback: significant decline in total revenue or margin driven by AOV drop or cannibalization in key segments (top customers, paid channels), or detected data/QA issues.

7. Communicate findings

• Prepare dashboard with the decomposition, segment charts, SKU-level tables, and recommended next steps. Provide clear business impact numbers and suggested mitigations (e.g., exclude discounted SKUs, tweak UX to upsell, or run targeted tests).